Sotera Health Company reported that Class I director James C. Neary resigned from the Board of Directors effective August 13, 2026. The resignation was voluntary and not due to any disagreement with the company regarding its operations or policies. Consequently, the board size was reduced to eleven directors. Sotera Health operates in the healthcare services industry, providing sterilization and infection prevention solutions.

Sotera Health Company reported second-quarter 2026 net income of $54 million ($0.19 per diluted share), up from $8 million in the prior year period, driven by high-single-digit revenue growth across its business units. The company raised its full-year 2026 outlook, projecting net revenues to grow 5.25% to 6.75% and Adjusted EBITDA to grow 5.75% to 7.25%, on a constant currency basis. Management cited strong execution in Sterigenics, Nordion, and Nelson Labs, alongside improved liquidity with approximately $950 million available and a net leverage ratio of 3.0x. Sotera Health operates as a leading global provider of mission-critical end-to-end sterilization solutions, lab testing, and advisory services for the healthcare industry.